Shopping Cart 0
Cart Subtotal
AED 0

Takeda Pharmaceutical Co Ltd (4502) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 1376
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Takeda Pharmaceutical Co Ltd (4502)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Takeda Pharmaceutical Company Ltd (Takeda) is a research-based global pharmaceutical company which focuses on the research and development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and consumer health care products. The company manufactures and markets a wide range of products including photographic chemicals, inorganic chemicals, vitamin bulks, test reagents and clinical diagnostics. Takeda markets its drugs worldwide through its subsidiaries in North America, Europe and Asia. It operates production facilities in Osaka and Hikari in Japan; Italy; Ireland; Germany; Austria; Denmark; Belgium; Norway; Poland; Russia; China; Indonesia; Mexico; Brazil; Argentina; Columbia; Estonia; and India. It also operates research and development facilities at various locations in Japan and the US, China and the UK; and in Brazil, Germany, Switzerland, and Singapore. Takeda is headquartered in Chuo-ku, Osaka, Japan.

Takeda Pharmaceutical Co Ltd Key Recent Developments

Dec 04,2018: Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas

Dec 03,2018: Riassunto: Takeda presenter dati positivi da TOURMALINE-MM3, il primo studio pivot di fase 3 controllato con placebo per la valutazione di un trattamento con inibitore del proteasoma nell'ambito di una terapia di mantenimento

Dec 02,2018: Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting

Dec 02,2018: Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting

Nov 22,2018: Takeda Voluntary Recalls 7 Narcotic Injectable Products after Confirming Coloring

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Takeda Pharmaceutical Co Ltd-Key Facts 6

Takeda Pharmaceutical Co Ltd-Key Employees 7

Takeda Pharmaceutical Co Ltd-Key Employee Biographies 8

Takeda Pharmaceutical Co Ltd-Major Products and Services 9

Takeda Pharmaceutical Co Ltd-History 11

Takeda Pharmaceutical Co Ltd-Company Statement 27

Takeda Pharmaceutical Co Ltd-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Joint Venture 35

Section 2-Company Analysis 37

Company Overview 37

Takeda Pharmaceutical Co Ltd-Business Description 38

Business Segment: Pharmaceutical Products 38

Overview 38

Performance 38

Geographical Segment: Asia 39

Performance 39

Geographical Segment: Europe and Canada 39

Performance 39

Geographical Segment: Japan 39

Performance 39

Geographical Segment: Latin America 39

Performance 39

Geographical Segment: Other 39

Performance 39

Geographical Segment: Russia/CIS 39

Performance 39

Geographical Segment: The US 39

Performance 39

Takeda Pharmaceutical Co Ltd-SWOT Analysis 40

SWOT Analysis-Overview 40

Takeda Pharmaceutical Co Ltd-Strengths 40

Takeda Pharmaceutical Co Ltd-Weaknesses 41

Takeda Pharmaceutical Co Ltd-Opportunities 42

Takeda Pharmaceutical Co Ltd-Threats 43

Takeda Pharmaceutical Co Ltd-Key Competitors 44

Section 3-Company Financial Ratios 45

Financial Ratios-Capital Market Ratios 45

Financial Ratios-Annual Ratios 46

Performance Chart 49

Financial Performance 49

Financial Ratios-Interim Ratios 50

Financial Ratios-Ratio Charts 51

Section 4-Company's Lifesciences Financial Deals and Alliances 52

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 53

Takeda Pharmaceutical Co Ltd, Recent Deals Summary 54

Section 5-Company's Recent Developments 55

Dec 04, 2018: Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas 55

Dec 04, 2018: Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas 57

Nov 21, 2018: Takeda gets conditional EC approval for USD 62bn Shire acquisition 59

Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 60

Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 62

Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 64

Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 66

Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 68

Nov 01, 2018: Riassunto: Takeda presenter dati su una vasta gamma di esigenze di trattamento per i tumori del sangue al 60 congresso annuale dell'American Society of Hematology 70

Oct 31, 2018: Takeda reports second quarter FY2018 results 71

Section 6-Appendix 73

Methodology 73

Ratio Definitions 73

About GlobalData 77

Contact Us 77

Disclaimer 77


List Of Figure

List of Figures

Takeda Pharmaceutical Co Ltd, Performance Chart (2014-2018) 49

Takeda Pharmaceutical Co Ltd, Ratio Charts 51

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 53


List Of Table

List of Tables

Takeda Pharmaceutical Co Ltd, Key Facts 6

Takeda Pharmaceutical Co Ltd, Key Employees 7

Takeda Pharmaceutical Co Ltd, Key Employee Biographies 8

Takeda Pharmaceutical Co Ltd, Major Products and Services 9

Takeda Pharmaceutical Co Ltd, History 11

Takeda Pharmaceutical Co Ltd, Other Locations 28

Takeda Pharmaceutical Co Ltd, Subsidiaries 29

Takeda Pharmaceutical Co Ltd, Joint Venture 35

Takeda Pharmaceutical Co Ltd, Key Competitors 44

Takeda Pharmaceutical Co Ltd, Ratios based on current share price 45

Takeda Pharmaceutical Co Ltd, Annual Ratios 46

Takeda Pharmaceutical Co Ltd, Annual Ratios (Cont...1) 47

Takeda Pharmaceutical Co Ltd, Annual Ratios (Cont...2) 48

Takeda Pharmaceutical Co Ltd, Interim Ratios 50

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 53

Takeda Pharmaceutical Co Ltd, Recent Deals Summary 54

Currency Codes 73

Capital Market Ratios 73

Equity Ratios 74

Profitability Ratios 74

Cost Ratios 75

Liquidity Ratios 75

Leverage Ratios 76

Efficiency Ratios 76

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Takeda Pharmaceutical Co Ltd, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Santen Pharmaceutical Co Ltd

Astellas Pharma Inc

Chugai Pharmaceutical Co Ltd

Kaken Pharmaceutical Co Ltd

Eisai Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Mochida Pharmaceutical Co Ltd

Sumitomo Chemical Co Ltd

GTx Inc

Rohto Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd (4502)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Takeda Pharmaceutical Company Ltd (Takeda) is a research-based global pharmaceutical company which focuses on the research and development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and consumer health care products. The company manufactures and markets a wide range of products including photographic chemicals, inorganic chemicals, vitamin bulks, test reagents and clinical diagnostics. Takeda markets its drugs worldwide through its subsidiaries in North America, Europe and Asia. It operates production facilities in Osaka and Hikari in Japan; Italy; Ireland; Germany; Austria; Denmark; Belgium; Norway; Poland; Russia; China; Indonesia; Mexico; Brazil; Argentina; Columbia; Estonia; and India. It also operates research and development facilities at various locations in Japan and the US, China and the UK; and in Brazil, Germany, Switzerland, and Singapore. Takeda is headquartered in Chuo-ku, Osaka, Japan.

Takeda Pharmaceutical Co Ltd Key Recent Developments

Dec 04,2018: Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas

Dec 03,2018: Riassunto: Takeda presenter dati positivi da TOURMALINE-MM3, il primo studio pivot di fase 3 controllato con placebo per la valutazione di un trattamento con inibitore del proteasoma nell'ambito di una terapia di mantenimento

Dec 02,2018: Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting

Dec 02,2018: Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting

Nov 22,2018: Takeda Voluntary Recalls 7 Narcotic Injectable Products after Confirming Coloring

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Takeda Pharmaceutical Co Ltd-Key Facts 6

Takeda Pharmaceutical Co Ltd-Key Employees 7

Takeda Pharmaceutical Co Ltd-Key Employee Biographies 8

Takeda Pharmaceutical Co Ltd-Major Products and Services 9

Takeda Pharmaceutical Co Ltd-History 11

Takeda Pharmaceutical Co Ltd-Company Statement 27

Takeda Pharmaceutical Co Ltd-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Joint Venture 35

Section 2-Company Analysis 37

Company Overview 37

Takeda Pharmaceutical Co Ltd-Business Description 38

Business Segment: Pharmaceutical Products 38

Overview 38

Performance 38

Geographical Segment: Asia 39

Performance 39

Geographical Segment: Europe and Canada 39

Performance 39

Geographical Segment: Japan 39

Performance 39

Geographical Segment: Latin America 39

Performance 39

Geographical Segment: Other 39

Performance 39

Geographical Segment: Russia/CIS 39

Performance 39

Geographical Segment: The US 39

Performance 39

Takeda Pharmaceutical Co Ltd-SWOT Analysis 40

SWOT Analysis-Overview 40

Takeda Pharmaceutical Co Ltd-Strengths 40

Takeda Pharmaceutical Co Ltd-Weaknesses 41

Takeda Pharmaceutical Co Ltd-Opportunities 42

Takeda Pharmaceutical Co Ltd-Threats 43

Takeda Pharmaceutical Co Ltd-Key Competitors 44

Section 3-Company Financial Ratios 45

Financial Ratios-Capital Market Ratios 45

Financial Ratios-Annual Ratios 46

Performance Chart 49

Financial Performance 49

Financial Ratios-Interim Ratios 50

Financial Ratios-Ratio Charts 51

Section 4-Company's Lifesciences Financial Deals and Alliances 52

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 53

Takeda Pharmaceutical Co Ltd, Recent Deals Summary 54

Section 5-Company's Recent Developments 55

Dec 04, 2018: Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas 55

Dec 04, 2018: Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas 57

Nov 21, 2018: Takeda gets conditional EC approval for USD 62bn Shire acquisition 59

Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 60

Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 62

Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 64

Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 66

Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 68

Nov 01, 2018: Riassunto: Takeda presenter dati su una vasta gamma di esigenze di trattamento per i tumori del sangue al 60 congresso annuale dell'American Society of Hematology 70

Oct 31, 2018: Takeda reports second quarter FY2018 results 71

Section 6-Appendix 73

Methodology 73

Ratio Definitions 73

About GlobalData 77

Contact Us 77

Disclaimer 77


List Of Figure

List of Figures

Takeda Pharmaceutical Co Ltd, Performance Chart (2014-2018) 49

Takeda Pharmaceutical Co Ltd, Ratio Charts 51

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 53


List Of Table

List of Tables

Takeda Pharmaceutical Co Ltd, Key Facts 6

Takeda Pharmaceutical Co Ltd, Key Employees 7

Takeda Pharmaceutical Co Ltd, Key Employee Biographies 8

Takeda Pharmaceutical Co Ltd, Major Products and Services 9

Takeda Pharmaceutical Co Ltd, History 11

Takeda Pharmaceutical Co Ltd, Other Locations 28

Takeda Pharmaceutical Co Ltd, Subsidiaries 29

Takeda Pharmaceutical Co Ltd, Joint Venture 35

Takeda Pharmaceutical Co Ltd, Key Competitors 44

Takeda Pharmaceutical Co Ltd, Ratios based on current share price 45

Takeda Pharmaceutical Co Ltd, Annual Ratios 46

Takeda Pharmaceutical Co Ltd, Annual Ratios (Cont...1) 47

Takeda Pharmaceutical Co Ltd, Annual Ratios (Cont...2) 48

Takeda Pharmaceutical Co Ltd, Interim Ratios 50

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 53

Takeda Pharmaceutical Co Ltd, Recent Deals Summary 54

Currency Codes 73

Capital Market Ratios 73

Equity Ratios 74

Profitability Ratios 74

Cost Ratios 75

Liquidity Ratios 75

Leverage Ratios 76

Efficiency Ratios 76

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Takeda Pharmaceutical Co Ltd, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Santen Pharmaceutical Co Ltd

Astellas Pharma Inc

Chugai Pharmaceutical Co Ltd

Kaken Pharmaceutical Co Ltd

Eisai Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Mochida Pharmaceutical Co Ltd

Sumitomo Chemical Co Ltd

GTx Inc

Rohto Pharmaceutical Co Ltd